Creative BioMart Decided to Enhance Facilities for Biosimilar Comparability Study Services

Creative BioMart, a world leading biotech company that specialized in providing protein, recombinant protein, GMP protein, cell line and protein-related services, decided to enhance its facilities for biosimilar comparability study services.

The current guidelines for biosimilar allow a reduced drug development programme, making entry to the market much faster for biosimilar manufacturers. Although the pathway to licensure for biosimilar is reduced when compared to that of a new product, these cannot be considered identical to the innovator product and a number of assessments are required to demonstrate comparability.
“For a corporate to survive in fierce competition, the first thing it should do is enhancing itself. Introducing advanced techniques, gathering elite professional, improving corporate culture are all key factors.” said chief marketing staff Linna Green in Creative BioMart. “Based on the current biosimilar study services we have, we decided to allocated 3 million dollars to introducing the latest technique and employ more experts in biosimilar study” Linna Green added.

Visit to know more about Creative BioMart’s current biosimilar comparability study services and to follow its update.
Article Link: Creative BioMart Decided to Enhance Facilities for Biosimilar Comparability Study Services


Related Press Release:

Discussion: Will Google Invest Bio-pharmaceuticals after Its Health-care Part
What Quality Collaboration Brings for Technology Transfer?
A Summary of Characteristics of the Bio-pharmaceutical Industry
Creative BioMart Released Star of the Year Awards This Monday
Creative BioMart Improved Its Biomarker Service
Blueprinting Proteins, Once Difficult Now Easier
Angiopoietin-1 Was Found to Has Control over Fish Brain Size and Intelligence